A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells

Cell Death and Disease

Volumn 6, Issue 3, 2015, Pages

  Chu, B ^a   Liu, F ^a   Li, L ^a   Ding, C ^a   Chen, K ^a   Sun, Q ^a   Shen, Z ^b   Tan, Y ^a   Tan, C ^a   Jiang, Y ^a,c  

^a TSINGHUA UNIVERSITY   (China)

^b Shenzhen Kivita Innovative Drug Discovery Institute   (China)

^c Tsinghua University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL; APOPTOSIS; BIOSYNTHESIS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MCF 7 CELL LINE; MOUSE; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZIMIDAZOLES; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MCF-7 CELLS; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84965090087     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/CDDIS.2015.25     Document Type: Article

References (49)

1. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014; 25: 282–303.
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Bio 2001; 2: 127–137.
3. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141: 1117–1134.
4. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 2003; 11: 495–505.
5. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 2012; 12: 553–563.
6. Ménard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003; 22: 6570–6578.
7. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Rel 2010; 146: 264–275.
8. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn Jr PA. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002; 29: 3–14.
9. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Tr 2012; 136: 331–345.
10. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1: 85–94.
11. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673–1684.
12. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659–1672.
13. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630–1639.
14. Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Proliferat 2012; 45: 487–498.
15. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305–1308.
16. Debatin K-M. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immun 2004; 53: 153–159.
17. Wang G, Wang X, Yu H, Wei S, Williams N, Holmes DL et al. Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. Nat Chem Biol 2013; 9: 84–89.
18. Dolloff NG, Mayes PA, Hart LS, Dicker DT, Humphreys R, El-Deiry WS. Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Sci Transl Med 2011; 3: 86ra50.
19. Zou W, Liu X, Yue P, Zhou Z, Sporn MB, Lotan R et al. c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res 2004; 64: 7570–7578.
20. Walia R, Md H, Naaz SF, Iqbal K, Lamba H. Benzimidazole derivatives – an overview. IJRPC 2011; 1: 565–574.
21. Kuş C, Ayhan-Kilcigil G, Özbey S, Kaynak FB, Kaya M, Çoban T et al. Synthesis and antioxidant properties of novel N-methyl-1, 3, 4-thiadiazol-2-amine and 4-methyl-2H-1, 2, 4-triazole-3 (4H)-thione derivatives of benzimidazole class. Eur J Med Chem 2008; 16: 4294–4303.
22. Keurulainen L, Salin O, Siiskonen A, Kern JM, Alvesalo J, Kiuru P et al. Design and synthesis of 2-arylbenzimidazoles and evaluation of their inhibitory effect against Chlamydia pneumoniae. J Med Chem 2010; 53: 7664–7674.
23. Sharma D, Narasimhan B, Kumar P, Jalbout A. Synthesis and QSAR evaluation of 2-(substituted phenyl)-1H-benzimidazoles and [2-(substituted phenyl)-benzimidazol-1-yl]-pyridin-3-yl-methanones. Eur J Med Chem 2009; 44: 1119–1127.
24. White AW, Curtin NJ, Eastman BW, Golding BT, Hostomsky Z, Kyle S et al. Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. Bioorg Med Chem Lett 2004; 14: 2433–2437.
25. Kim JS, Gatto B, Yu C, Liu A, Liu LF, LaVoie EJ. Substituted 2, 5'-Bi-1H-benzimidazoles: topoisomerase I inhibition and cytotoxicity. J Med Chem 1996; 39: 992–998.
26. Neff DK, Lee-Dutra A, Blevitt JM, Axe FU, Hack MD, Buma JC et al. 2-Aryl benzimidazoles featuring alkyl-linked pendant alcohols and amines as inhibitors of checkpoint kinase Chk2. Bioorg Med Chem Lett 2007; 17: 6467–6471.
27. Li Y, Tan C, Gao C, Zhang C, Luan X, Chen X et al. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors. Bioorgan Med Chem 2011; 19: 4529–4535.
28. Yadav S, Sinha D, Singh SK, Singh VK. Novel benzimidazole analogs as inhibitors of EGFR tyrosine kinase. Chem Biol Drug Des 2012; 80: 625–630.
29. Bodmer J-L, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000; 2: 241–243.
30. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000; 12: 599–609.
31. Lacroix M, Toillon R-A, Leclercq G. P53 and breast cancer, an update. Endocr-Relat Cancer 2006; 13: 293–325.
32. Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 2014; 25: 304–317.
33. Pourazar J, Blomberg A, Kelly FJ, Davies DE, Wilson SJ, Holgate ST et al. Diesel exhaust increases EGFR and phosphorylated C-terminal Tyr 1173 in the bronchial epithelium. Part Fibre Toxicol 2008; 5: 8.
34. Schulze WX, Deng L, Mann M. Phosphotyrosine interactome of the ErbB‐receptor kinase family. Mol Syst Biol 2005; 1: 0008.
35. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341–354.
36. Montgomery RB, Makary E, Schiffman K, Goodell V, Disis ML. Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res 2005; 65: 650–656.
37. Faber AC, Wong K-K, Engelman JA. Differences underlying EGFR and HER2 oncogene addiction. Cell Cycle 2010; 9: 851–852.
38. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857–868.
39. Yang J-Y, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 2008; 10: 138–148.
40. Asada S, Daitoku H, Matsuzaki H, Saito T, Sudo T, Mukai H et al. Mitogen-activated protein kinases, Erk and p38, phosphorylate and regulate Foxo1. Cell Signal 2007; 19: 519–527.
41. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231–241.
42. Medema RH, Kops GJ, Bos JL, Burgering BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000; 404:782–787.
43. Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 2004; 117: 421–426.
44. Engel T, Henshall DC. Apoptosis, Bcl-2 family proteins and caspases: the ABCs of seizure-damage and epileptogenesis? IJPPP 2009; 1: 97.
45. Scheid MP, Schubert KM, Duronio V. Regulation of Bad phosphorylation and association with Bcl-xL by the MAPK/Erk kinase. J Biol Chem 1999; 274: 31108–31113.
46. del Peso L, González-García M, Page C, Herrera R, Nuñez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997; 278: 687–689.
47. Dijkers PF, Lammers J-WJ, Koenderman L, Coffer PJ. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 2000; 10: 1201–1204.
48. Inoue S, Twiddy D, Dyer M, Cohen G. Upregulation of TRAIL-R2 is not involved in HDACi mediated sensitization to TRAIL-induced apoptosis. Cell Death Differ 2006; 13: 2160–2162.
49. Koschny R, Ganten TM, Sykora J, Haas TL, Sprick MR, Kolb A et al. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer‐specific apoptosis within a therapeutic window. Hepatology 2007; 45: 649–658.